Preferential activation of type I interferon-mediated antitumor inflammatory signaling by CuS/MnO₂/diAMP nanoparticles enhances anti-PD-1 therapy for sporadic colorectal cancer.

ABSTRACT: Converting the "cold" tumor microenvironment (TME) to a "hot" milieu has become the prevailing approach for enhancing the response of immune-excluded/immunosuppressed colorectal cancer (CRC) patients to immune checkpoint blockade (ICB) therapy. During this process, inflammation accompanied by different kinds of chemokines/cytokines inevitably occurs. However, some activated inflammatory signals exhibit protumor potency. Therefore, strategies that preferentially activate antitumor inflammatory signaling rather than tumor-promoting signaling need to be developed. Herein, we constructed a STING agonist-loaded CuS/MnO₂ bimetallic nanosystem, termed diAMP-BCM. BCM with an optimized Cu/Mn ratio efficiently promoted the activation of proinflammatory signaling, and in combination with t

SUBMITTER: Peng J 

PROVIDER: S-EPMC11555826 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature